BMO Capital Reiterates Outperform Rating on Merus N.V. (MRUS)

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/12/2026

1. ORCL
2. SPY
3. SPCX
4. USO
5. CHWY
6. NAVN
7. HUMA
8. NVDA
9. CRWV
10. CME

Go back to BMO Capital Reiterates Outperform Rating on Merus N.V. (MRUS)

Merus N.V. (MRUS) PT Raised to $84 at BMO Capital

May 28, 2024 11:51 AM UTC

BMO Capital analyst Etzer Darout raised the price target on Merus N.V. (NASDAQ: MRUS) to $84.00 (from $58.00) while maintaining a Outperform rating.

The analyst comments "We're updating our model following MRUS's pre-ASCO petosemtamab plus pembrolizumab combination update in 1L head and neck cancers... More

BMO Capital Reiterates Outperform Rating on Merus N.V. (MRUS)

May 28, 2024 8:13 AM UTC

BMO Capital analyst Etzer Darout reiterated an Outperform rating and $58.00 price target on Merus N.V. (NASDAQ: MRUS).

The analyst comments "MRUS announced updated data from the Phase 1/2 trial evaluating petosemtamab/ pembrolizumab in 1L HNSCC patients, reporting a 67% ORR in 24 patients, including a 75%... More

Merus (MRUS) Announces Publication of an Abstract on Petosemtamab with Pembrolizumab as 1L treatment of r/m HNSCC at the 2024 ASCO Annual Meeting

May 24, 2024 7:38 AM UTC

Merus N.V. (Nasdaq: MRUS) (Merus, the Company, we, or our), a clinical-stage oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced the publication of an abstract regarding petosemtamab in combination with pembrolizumab on the 2024 American Society of Clinical Oncology® (ASCO®) Annual Meeting... More